Exons of Leukemia Suppressor Genes: Creative Assembly Required.

Abstract:

:Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini and acting in loss-of-function or dominant-negative manners.

journal_name

Trends Cancer

journal_title

Trends in cancer

authors

Asnani M,Thomas-Tikhonenko A

doi

10.1016/j.trecan.2018.10.005

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

796-798

issue

12

eissn

2405-8033

issn

2405-8025

pii

S2405-8033(18)30223-1

journal_volume

4

pub_type

杂志文章,评审
  • Metronomic Maintenance Therapy for Rhabdomyosarcoma.

    abstract::In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully ...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2019.10.004

    authors: André N,Corradini N,Shaked Y

    更新日期:2019-12-01 00:00:00

  • Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges.

    abstract::Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.11.007

    authors: Yang Z,Gimple RC,Zhou N,Zhao L,Gustafsson JÅ,Zhou S

    更新日期:2020-12-16 00:00:00

  • Cancer Genomics in Clinical Context.

    abstract::Precision medicine requires appropriate application of genomics in clinical practice. In cancer, we have witnessed practice-changing examples of how genomic knowledge is translated into more tailored and effective therapies. The next opportunity is to embed cancer genomics in clinical context so that patient-centric l...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2015.07.010

    authors: Chin L,Wargo JA,Spring DJ,Kantarjian H,Futreal PA

    更新日期:2015-09-01 00:00:00

  • Noninvasive PET Imaging of T cells.

    abstract::The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.03.009

    authors: Wei W,Jiang D,Ehlerding EB,Luo Q,Cai W

    更新日期:2018-05-01 00:00:00

  • Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer.

    abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.11.008

    authors: Nizzero S,Shen H,Ferrari M,Corradetti B

    更新日期:2020-01-01 00:00:00

  • Exercise Benefits Meet Cancer Immunosurveillance: Implications for Immunotherapy.

    abstract::Regular exercise reduces the risk of cancer. One potential mechanism for this efficacy is improved antitumor immunity. This is an important issue because evading immune destruction is a hallmark of cancer and immunotherapy is reshaping cancer treatment. Here we review recent developments reported by Wennerberg et al.,...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.12.003

    authors: Fiuza-Luces C,Valenzuela PL,Castillo-García A,Lucia A

    更新日期:2021-02-01 00:00:00

  • Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.

    abstract::Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators o...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.01.004

    authors: Shah B,Zhao X,Silva AS,Shain KH,Tao J

    更新日期:2018-03-01 00:00:00

  • Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.

    abstract::Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.01.003

    authors: Gargalionis AN,Papavassiliou AG

    更新日期:2017-03-01 00:00:00

  • Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.

    abstract::Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research ha...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.06.005

    authors: Ramesh V,Brabletz T,Ceppi P

    更新日期:2020-11-01 00:00:00

  • The Emerging Role of ABL Kinases in Solid Tumors.

    abstract::The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.07.004

    authors: Wang J,Pendergast AM

    更新日期:2015-10-01 00:00:00

  • Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

    abstract::Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.07.002

    authors: García-Gómez R,Bustelo XR,Crespo P

    更新日期:2018-09-01 00:00:00

  • Emerging role of mTOR in the response to cancer therapeutics.

    abstract::The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. T...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2016.03.008

    authors: Ilagan E,Manning BD

    更新日期:2016-05-01 00:00:00

  • Cancer of Unknown Primary in the Molecular Era.

    abstract::Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.11.002

    authors: Kato S,Alsafar A,Walavalkar V,Hainsworth J,Kurzrock R

    更新日期:2021-01-27 00:00:00

  • DUBs, Hypoxia, and Cancer.

    abstract::Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.08.005

    authors: Mennerich D,Kubaichuk K,Kietzmann T

    更新日期:2019-10-01 00:00:00

  • Redox Debt Leads to Metabolic Bankruptcy in Tumors.

    abstract::Lactate dehydrogenase (LDH) accounts for the fermentative component of aerobic glycolysis, a near ubiquitous metabolic alteration in cancer. Recently, Oshima et al. developed a bioavailable LDH inhibitor that decreases tumor growth in mice and functions synergistically with mitochondrial respiration inhibitors. These ...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.02.012

    authors: Quon E,Hart ML,Sullivan LB

    更新日期:2020-05-01 00:00:00

  • A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.

    abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.05.014

    authors: Gill J,Cetnar JP,Prasad V

    更新日期:2020-09-01 00:00:00

  • Understanding the Cause and Consequence of Tumor Heterogeneity.

    abstract::Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.01.010

    authors: Khatib S,Pomyen Y,Dang H,Wang XW

    更新日期:2020-04-01 00:00:00

  • Prolonging Reproductive Life after Cancer: The Need for Fertoprotective Therapies.

    abstract::The survival rate of reproductive-age patients with cancer is increasing, reflecting the advent of better and more efficient therapies. Cancer survivors seek the resumption of a normal and healthy life, which often includes starting a family. Unfortunately, many cancer treatments increase the risk of premature ovarian...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.03.006

    authors: Woodard TL,Bolcun-Filas E

    更新日期:2016-05-01 00:00:00

  • Biophysical Properties of Extracellular Matrix: Linking Obesity and Cancer.

    abstract::Obesity has been associated with increased severity of diagnoses for several types of cancer, and recent evidence suggests that the mechanism by which obese tissues contribute to cancer progression involves the extracellular matrix (ECM). Understanding the physicochemical differences between lean and obese ECM, and ho...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.02.001

    authors: Druso JE,Fischbach C

    更新日期:2018-04-01 00:00:00

  • Plastic Heterogeneity of Innate Lymphoid Cells in Cancer.

    abstract::Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.03.008

    authors: Wagner M,Moro K,Koyasu S

    更新日期:2017-05-01 00:00:00

  • Transforming Biomarker Development with Exceptional Responders.

    abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.11.004

    authors: Jonsson P,Taylor BS

    更新日期:2018-01-01 00:00:00

  • CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.

    abstract::Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.09.010

    authors: Pereira BA,Vennin C,Papanicolaou M,Chambers CR,Herrmann D,Morton JP,Cox TR,Timpson P

    更新日期:2019-11-01 00:00:00

  • Translin-Trax: Considerations for Oncological Therapeutic Targeting.

    abstract::Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.02.014

    authors: McFarlane RJ,Wakeman JA

    更新日期:2020-06-01 00:00:00

  • New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?

    abstract::Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host int...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.11.006

    authors: Slade DJ

    更新日期:2020-12-09 00:00:00

  • In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2016.07.002

    authors: Schneider G,Saur D

    更新日期:2016-08-01 00:00:00

  • Turning Cold into Hot: Firing up the Tumor Microenvironment.

    abstract::Cancers develop within complex tissue environments consisting of diverse innate and adaptive immune cells, along with stromal cells, vascular networks, and many other cellular and noncellular components. The high heterogeneity within the tumor microenvironment (TME) remains a key obstacle in understanding and treating...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.02.022

    authors: Duan Q,Zhang H,Zheng J,Zhang L

    更新日期:2020-07-01 00:00:00

  • Fanconi Anemia Signaling and Cancer.

    abstract::The extremely high cancer incidence associated with patients suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA genes. Over the course of human tumor development, FA genes perform critical tumor-suppression roles. In doing so, FA provides researchers with a unique genet...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.10.005

    authors: Nepal M,Che R,Zhang J,Ma C,Fei P

    更新日期:2017-12-01 00:00:00

  • Repurposing Drugs in Oncology: Next Steps.

    abstract::The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2017.06.007

    authors: Verbaanderd C,Meheus L,Huys I,Pantziarka P

    更新日期:2017-08-01 00:00:00

  • Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

    abstract::Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.11.010

    authors: Lønning PE

    更新日期:2020-12-22 00:00:00

  • TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

    abstract::TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.01.007

    authors: Shahbandi A,Nguyen HD,Jackson JG

    更新日期:2020-02-01 00:00:00